Wednesday, February 22, 2023
Moderna announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit's suite of proprietary gene editing technologies, including base editing, with Moderna's mRNA platform to advance in vivo gene editing therapies against a select set of therapeutic targets. mRNA holding the promise in the delivery of gene-editing technology, consists of the potential to treat or cure rare genetic and other diseases.
This collaboration with Life Edit, will harness the power of gene editing technologies, part of broader research and development engine, which helps to advance mission and deliver on the promise of mRNA. Moreover, this collaboration between Life Edit and Moderna demonstrates the strength of respective technologies to advance programmable medicines to more specifically target disease.
Under the agreement, Life Edit and Moderna will collaborate on research and preclinical studies funded by Moderna. Upon exercising an option for a target, Moderna will assume responsibility for further development, manufacturing, and commercialisation.
